Liposomal Bupivacaine after Surgery for the Management of Pain after Mastectomy
This phase II trial compares the effect of liposomal bupivacaine (Exparel) for pain control (analgesia) after mastectomy (surgical removal of the breast tissue) to standard of care bupivacaine or a placebo. Local anesthetic may be administered at the end of surgery to decrease pain after surgery. Bupivacaine given at the end of mastectomy has been previously shown to decrease patient's pain and opioid use after surgery, and increase patient satisfaction. Exparel is a newer, longer-acting form of bupivacaine. The purpose of this study is compare the effect of Exparel (liposomal) to standard bupivacaine or placebo in managing pain, decreasing overall narcotic use, and improving patient satisfaction after mastectomy and immediate, prosthetic breast reconstruction.